Principal Financial Group
AKBA icon

Principal Financial Group’s Akebia Therapeutics AKBA Stock Holding History

Principal Financial Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.9K Buy
18,312
+6,324
+53% +$7.53K ﹤0.01% 2147
2026
Q1 		$16.7K Sell
11,988
-313,902
-96% -$431K ﹤0.01% 2169
2025
Q4 		$525K Buy
325,890
+99,277
+44% +$208K ﹤0.01% 2040
2025
Q3 		$619K Buy
226,613
+209,664
+1,237% +$697K ﹤0.01% 2014
2025
Q2 		$61.7K Buy
16,949
+2,632
+18% +$7.23K ﹤0.01% 2187
2025
Q1 		$27.5K Buy
14,317
+2,096
+17% +$4.28K ﹤0.01% 2140
2024
Q4 		$23.2K Sell
12,221
-3,556
-23% -$6.17K ﹤0.01% 2196
2024
Q3 		$20.8K Sell
15,777
-5,336
-25% -$7.13K ﹤0.01% 2208
2024
Q2 		$21.5K Buy
+21,113
New +$26.1K ﹤0.01% 2336
2022
Q4 		– Sell
-164,028
Closed -$52K – 2443
2022
Q3 		$52K Sell
164,028
-250,364
-60% -$98.2K ﹤0.01% 2408
2022
Q2 		$146K Buy
414,392
+229,453
+124% +$96.3K ﹤0.01% 2343
2022
Q1 		$132K Sell
184,939
-73,624
-28% -$158K ﹤0.01% 2400
2021
Q4 		$584K Sell
258,563
-281,269
-52% -$767K ﹤0.01% 2089
2021
Q3 		$1.55M Sell
539,832
-8,036
-1% -$22.9K ﹤0.01% 1912
2021
Q2 		$2.08M Sell
547,868
-25,369
-4% -$85.4K ﹤0.01% 1897
2021
Q1 		$1.94M Buy
573,237
+36,084
+7% +$130K ﹤0.01% 1859
2020
Q4 		$1.5M Buy
537,153
+402,876
+300% +$1.18M ﹤0.01% 1857
2020
Q3 		$337K Buy
134,277
+40,743
+44% +$358K ﹤0.01% 2110
2020
Q2 		$1.27M Buy
93,534
+63,000
+206% +$652K ﹤0.01% 1780
2020
Q1 		$231K Buy
30,534
+13,183
+76% +$103K ﹤0.01% 2033
2019
Q4 		$110K Sell
17,351
-11,049
-39% -$52.5K ﹤0.01% 2180
2019
Q3 		$111K Buy
28,400
+10,527
+59% +$45.1K ﹤0.01% 2176
2019
Q2 		$87K Buy
17,873
+6,664
+59% +$37.9K ﹤0.01% 2188
2019
Q1 		$92K Sell
11,209
-1,593
-12% -$10.9K ﹤0.01% 2158
2018
Q4 		$71K Buy
+12,802
New +$100K ﹤0.01% 2185

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Principal Financial Group's AKBA Position: Q2 2026 in Review

Principal Financial Group increased its Akebia Therapeutics (AKBA) stake by 53% in Q2 2026, buying an estimated $7.53K and bringing the position to 18,312 shares worth $20.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2147.

Principal Financial Group first reported a position in AKBA in Q4 2018 and has held it in 25 quarters since. The position peaked at $2.08M in Q2 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Principal Financial Group held 18,312 shares of Akebia Therapeutics worth $20.9K as of Q2 2026.
  • Principal Financial Group bought 6,324 Akebia Therapeutics shares in Q2 2026, an estimated $7.53K.
  • Akebia Therapeutics made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #2147 holding.
  • Principal Financial Group first reported a position in Akebia Therapeutics in Q4 2018 and has held it in 25 quarters since.
  • Principal Financial Group's Akebia Therapeutics position peaked at $2.08M in Q2 2021.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.